Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin's diffuse large B-cell lymphoma.
Rituximab is a treatment option to non-Hodg kin's diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.
Cervera Grau
J M
JM
Oncology Department, Hospital General de Elda, Elda, Alicante, Spain. cerveragrau@yahoo.es
Esquerdo Galiana
G
G
Belso Candela
A
A
Llorca Ferrándiz
C
C
Juárez Marroquí
A
A
Maciá Escalante
S
S
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D054537:Atrioventricular Block / Q000139:chemically induced*; D050171:Dyslipidemias / Q000150:complications; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000503:physiopathology; D000069283:Rituximab; D013128:Spinal Osteophytosis / Q000150:complications; D020521:Stroke / Q000150:complications; D020246:Venous Thrombosis / Q000150:complications
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab